Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RyboDyn Selected to Join Lilly Gateway Labs  | Contract Pharma

What are you searching for?

Sign in
Breaking News

RyboDyn Selected to Join Lilly Gateway Labs 

Aims to advance next-gen immunotherapies targeting the dark proteome.

RyboDyn, Inc., a biotechnology company pioneering immunotherapies targeting the dark proteome, has been selected to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Lilly’s global scientific and business network to advance its lead programs.

Through its sequencing and AI-driven platform, RyboCypher, RyboDyn has uncovered a new class of therapeutic targets that are cancer-specific, abundantly expressed on the cell surface, and absent in healthy tissues. In collaboration with Moffitt Cancer Center, RyboDyn recently demonstrated that several of these Dark Targets are conserved across patients, supporting their potential as the foundation for first-in-class precision immunotherapies.

“We’re thrilled to join the LGL community and collaborate with peers who share our urgency to translate high-impact science,” said Imad Ajjawi, PhD, MBA, CEO and Co-founder of RyboDyn. “Lilly’s support comes at a pivotal moment as we advance our first wave of programs toward therapeutic development.”

RyboDyn’s LGL residency is part of the Lilly Catalyze360 model, which aims to empower early-stage biotech startups across all therapeutic areas by providing access to world-class lab space and drug development talent and resources through Lilly Gateway Labs, Lilly ExploR&D, and Lilly Ventures.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics